What Is a Bariatric Centre? UK Guide

A bariatric centre is a specialist medical facility dedicated to the comprehensive assessment, treatment and long-term management of obesity and its related health conditions. These centres bring together multidisciplinary teams including specialist doctors, dietitians, psychologists and bariatric surgeons to address the metabolic, psychological and physical factors that drive obesity as a chronic condition. Whether NHS-based or private, bariatric centres offer a structured pathway that may include lifestyle intervention, pharmacotherapy and surgery. Understanding what a bariatric centre does, who qualifies and how to choose one can help patients make informed decisions about their care.

What is a bariatric centre and what does it actually do?

A bariatric centre is a specialist facility providing multidisciplinary assessment, treatment and long-term follow-up for obesity. In the UK, services are organised into Tier 3 (non-surgical) and Tier 4 (surgical) pathways, aligned with NICE guidance.

A bariatric centre is a specialist medical facility that provides comprehensive assessment, treatment and long-term follow-up for people living with obesity and its related health conditions. The word "bariatric" derives from the Greek for weight, and these centres bring together a multidisciplinary team, typically including specialist doctors, dietitians, psychologists, specialist nurses and, where surgery is offered, bariatric surgeons. Their purpose is not simply to help patients lose weight, but to address the underlying metabolic, psychological and physical factors that contribute to obesity as a chronic condition.

Bariatric centres operate on the principle that obesity requires sustained, coordinated care rather than a single intervention. A patient's journey usually begins with a thorough clinical assessment covering body mass index (BMI), comorbidities such as type 2 diabetes, hypertension and sleep apnoea, mental health, dietary history and previous weight-management attempts. This information shapes an individualised treatment plan that may combine lifestyle intervention, pharmacotherapy and, in appropriate cases, surgery.

In the UK, specialist weight-management services are organised broadly into tiers. Tier 3 services provide non-surgical specialist input, including dietetic, psychological and medical support, and engagement with a Tier 3 service is typically required before NHS-funded surgery is considered. Tier 4 services encompass bariatric surgery and are delivered in hospital settings with dedicated surgical teams. Bariatric centres may be NHS-based, operating under referral pathways aligned with NICE guidance, or privately run. Regardless of setting, a reputable centre will offer structured follow-up over months or years, recognising that weight management is a long-term endeavour rather than a short-term fix. Patients are usually referred via their GP, who can direct them to the appropriate local pathway.

What treatments and services can you expect at a bariatric centre?

Bariatric centres offer lifestyle programmes, licensed pharmacotherapy including orlistat, liraglutide, semaglutide, tirzepatide and orforglipron, and surgical procedures such as gastric bypass or sleeve gastrectomy. Treatment is tailored to each patient's clinical profile.

Bariatric centres offer a broad range of treatments spanning lifestyle intervention, pharmacological therapy and surgical procedures, tailored to each patient's clinical profile and preferences. The starting point for most patients is a structured programme of dietary counselling, physical activity guidance and behavioural support, delivered by dietitians and psychologists. These programmes are evidence-based and form the foundation of care regardless of whether other treatments are added.

Where lifestyle measures alone are insufficient, pharmacotherapy may be considered. Medicines currently licensed in the UK for weight management include orlistat; liraglutide (Saxenda); semaglutide injection (Wegovy, available in doses up to 2.^[13][14]4 mg weekly, with a higher-dose 7.2 mg weekly formulation also MHRA-authorised); and tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist that is MHRA-authorised both for type 2 diabetes and for chronic weight management.^[3][11] Orforglipron (Foundayo) is a further UK-licensed oral option for weight management.^[4] It is important to note that MHRA marketing authorisation and NICE recommendation are distinct: local Integrated Care Boards (ICBs) make commissioning decisions that determine which medicines are available on the NHS in a given area, and not all licensed medicines will be routinely funded. A prescriber at a bariatric centre will assess suitability, monitor for adverse effects such as nausea, vomiting or gastrointestinal discomfort, and adjust treatment accordingly. Patients who are pregnant, planning a pregnancy or breastfeeding should discuss this with their prescriber before starting any of these medicines, as the SmPCs for GLP-1 and GIP/GLP-1 receptor agonists advise against use in these circumstances.

For patients who meet specific clinical criteria, bariatric surgery is available. Procedures such as Roux-en-Y gastric bypass, sleeve gastrectomy and adjustable gastric banding are performed at centres with dedicated surgical teams. Post-operative care, including nutritional supplementation and psychological support, is an integral part of the surgical pathway. Many centres also offer endoscopic procedures such as intragastric balloon placement as a less invasive intermediate option; NHS availability of endoscopic procedures is limited and service-dependent, and NICE has published interventional procedures guidance on their use.^[18]

If you experience a suspected side effect from any medicine prescribed at a bariatric centre, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Who qualifies for treatment at a bariatric centre in the UK?

NHS-funded bariatric surgery is recommended by NICE for adults with a BMI of 35 or above with a comorbidity, or 40 or above, following engagement with Tier 3 services. Pharmacotherapy eligibility is set by individual NICE technology appraisals and local ICB commissioning.

Eligibility for treatment at a bariatric centre in the UK depends on the type of intervention being considered and whether care is accessed through the NHS or privately. For NHS-funded bariatric surgery, NICE guidance recommends referral for adults with a BMI of 35 or above who have at least one obesity-related comorbidity, or for adults with a BMI of 40 or above regardless of comorbidities, provided they have engaged with non-surgical weight-management services. NICE also recommends earlier surgical consideration for people of South Asian, Chinese, Black African or Black Caribbean family background at lower BMI thresholds, reflecting differing metabolic risk profiles, and for adults with type 2 diabetes where surgery may offer particular metabolic benefit.^[8] Engagement with a specialist non-surgical service (Tier 3) is typically a prerequisite for NHS-funded surgery.^[7][8] Patients should verify the current NICE guideline number and thresholds with their GP or specialist, as guidance is periodically updated.

For pharmacological treatment, eligibility criteria vary by medicine and are set out in the relevant NICE technology appraisals. Wegovy (semaglutide injection) is recommended by NICE for adults with a BMI of 35 or above and at least one weight-related comorbidity, within a specialist weight-management service.^[6][7] Mounjaro (tirzepatide) has its own NICE technology appraisal guidance. In both cases, local ICB commissioning decisions determine NHS availability in practice, and not all eligible patients will have access in every area. Orforglipron (Foundayo) is licensed in the UK; its NICE appraisal status should be confirmed with a prescriber or via the NICE website, as guidance may be in development or recently published.

Private bariatric centres generally apply clinical criteria aligned with NICE thresholds, though they may offer assessment to a broader range of patients. Regardless of route, a thorough psychological assessment is standard, as readiness for behavioural change and the absence of untreated eating disorders are important factors in treatment outcomes. Patients with certain contraindications, such as hypersensitivity to a prescribed medicine, will not be offered that specific treatment, and the clinical team will discuss alternatives.

What should you look for when choosing a bariatric centre?

Look for CQC registration, adherence to BOMSS guidance, a full multidisciplinary team and transparent outcomes data. Confirm that any prescriber is GMC-registered and any pharmacy holds GPhC or PSNI registration.

When choosing a bariatric centre, the most important factors are clinical accreditation, the breadth of the multidisciplinary team, and the quality of long-term follow-up offered. In the UK, NHS bariatric services are commissioned and overseen by Integrated Care Boards (ICBs) and are subject to NHS quality standards. Private centres should ideally follow guidance from the British Obesity and Metabolic Surgery Society (BOMSS), which publishes standards and patient information for bariatric care; patients should check whether a centre follows BOMSS guidance rather than assuming formal accreditation exists. Independent healthcare providers in England should be registered with the Care Quality Commission (CQC), which publishes inspection reports at cqc.org.uk. In Scotland, independent providers are regulated by Healthcare Improvement Scotland; in Wales by Healthcare Inspectorate Wales; and in Northern Ireland by the Regulation and Quality Improvement Authority (RQIA). Checking the relevant regulator's register and inspection reports is a straightforward way to assess a centre's standards.

A reputable centre will be transparent about its outcomes data, including complication rates for surgical procedures and average weight-loss results across its patient population. It should offer a named clinical contact, clear escalation pathways if problems arise, and structured follow-up appointments rather than a single consultation. Psychological support should be embedded in the pathway, not offered as an optional add-on.

For patients exploring non-surgical options, including pharmacotherapy, some services are now available through regulated online providers. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support; medicines such as Mounjaro may be one option a prescriber considers following a consultation where it is clinically appropriate. Whether care is delivered in person or online, patients should confirm that the prescriber is registered with the General Medical Council (GMC), verifiable at gmc-uk.org, and that the pharmacy is registered with the GPhC (for pharmacies in Great Britain) or the Pharmaceutical Society of Northern Ireland (PSNI) for pharmacies in Northern Ireland. Avoid any provider that offers medicines without a clinical consultation or that cannot demonstrate regulatory registration.

Frequently Asked Questions